BillionToOne, Inc. - Class A common stock (BLLN)
Healthcare › Services-Medical Laboratories
Price History
Feb 9, 2026 — Aug 19, 2026Investment Snapshot
- Trading 816% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 5.9% — below-average profitability
- Revenue growing at 100% annually
BillionToOne, Inc. - Class A common stock (BLLN) is a Healthcare company operating in Services-Medical Laboratories, listed on the NASDAQ , with a market capitalisation of $5.6 billion . Key value metrics: P/E ratio 179.4, P/B ratio 10.52, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
BillionToOne, Inc. - Class A common stock — Fundamental Analysis Summary
BillionToOne, Inc. - Class A common stock (BLLN) is currently trading 816% above its Graham Number of $13.36, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 179.4x.
On financial health, BLLN shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 5.9% (sector average: -20.1%), and minimal leverage with a debt-to-equity ratio of 0.17.
StockPik's composite Value Score for BLLN is 49/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BLLN reports a high gross margin of 70.1% (sector average: 37.4%) and a modest operating margin of 8.5%.
BLLN shows revenue growing at 100% year-over-year, with earnings growing at 118%.